How These Healthcare Stocks are Faring? -- Healthways, Antares Pharma, HEALTHSOUTH, and MEDNAX

Monday, November 21, 2016 Drug News
Email Print This Page Comment

NEW YORK, November 21, 2016 /PRNewswire/ --

On Friday, November 18, 2016, major US

indices such as the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower to finish the session in bearish territories. The markets were also mostly in the red as losses were broad based with six out of nine sectors ending
the day in negative. Looking at last week overall markets' performance, Stock-Callers lined up the following Healthcare equities: Healthways Inc. (NASDAQ: HWAY), Antares Pharma Inc. (NASDAQ: ATRS), HEALTHSOUTH Corporation (NYSE: HLS), and MEDNAX Inc. (NYSE: MD). Download the free research reports on these stocks today:


Franklin, Tennessee headquartered Healthways Inc.'s stock edged 0.90% lower, to close the day at $22.00. The stock recorded a trading volume of 795,034 shares, which was above its three months average volume of 739,560 shares. Healthways' shares have surged 68.97% in the past one year. Shares of the Company, which together with its subsidiaries, provides network delivered solutions and population health management services to help people to enhance well-being and health, are trading 34.79% above its 200-day moving average. Additionally, the stock traded at a PE ratio of 33.54 and has a Relative Strength Index (RSI) of 40.60.

On November 8th, 2016, research firm UBS upgraded the Company's stock rating from 'Sell' to 'Buy'. The research firm also revised upwards its previous target price from $22.50 to $24. See our free and comprehensive research report on HWAY at:

Antares Pharma

On Friday, shares in Ewing, New Jersey headquartered Antares Pharma Inc. ended the session 4.86% higher at $1.94 with a total volume of 926,878 shares traded. Antares Pharma's shares have surged 14.12% in the last one month, 67.24% in the previous three months, and 49.23% in the past one year. The stock is trading 15.96% above its 50-day moving average and 66.40% above its 200-day moving average. Moreover, shares of the Company, which focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide, have an RSI of 63.88. ATRS free research report PDF is just a click away at:


Birmingham, Alabama headquartered HEALTHSOUTH Corp.'s stock finished Friday's session 0.27% higher at $40.97 with a total volume of 787,767 shares traded. Over the last one month and the previous three months, HEALTHSOUTH's shares have advanced 2.71% and 2.41%, respectively. Furthermore, the stock has gained 23.89% in the past one year. Shares of the Company, which owns and operates inpatient rehabilitation hospitals, home health agencies, and hospice agencies in the US, are trading above its 50-day and 200-day moving averages by 1.78% and 5.87%, respectively. HEALTHSOUTH's stock traded at a PE ratio of 16.67 and has an RSI of 55.14.

On November 9th, 2016, research firm Mizuho downgraded the Company's stock rating from 'Buy' to 'Neutral'. Sign up for your complimentary report on HLS at:


On Friday, shares in Sunrise, Florida-based MEDNAX Inc. recorded a trading volume of 343,949 shares, lower than their three months average volume of 659,680 shares. The stock ended the day 0.76% lower at $63.88. Shares of the Company are trading at a PE ratio of 17.52. MEDNAX's stock is trading below its 50-day and 200-day moving averages by 1.13% and 4.96%, respectively. Furthermore, shares of MEDNAX, which together with its subsidiaries, provides neonatal, anesthesia, maternal-fetal, and other pediatric subspecialties physician services in the US and Puerto Rico, have an RSI of 52.58.

On November 9th, 2016, research firm Mizuho downgraded the Company's stock rating from 'Buy' to 'Neutral', issuing a target price of $64 per share. Register for free on and download the latest research report on MD at:

Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store